MedTrace Logo

Copanlisib Plus Ibrutinib or Acalabrutinib in R/R CLL

NCT04685915 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2025-05-22

No results posted yet for this study

Summary

This research study is examining the effect of adding a fixed duration of copanlisib to ibrutinib or acalabrutinib in select participants who have been on ibrutinib or acalabrutinib for at least six months for relapsed/refractory chronic lymphocytic leukemia (CLL).

The names of the study drugs involved in this study are:

* Copanlisib
* Ibrutinib
* Acalabrutinib

Conditions

  • Chronic Lymphocytic Leukemia (CLL)

Interventions

DRUG

Ibrutinib

Capsule, taken by mouth once daily

DRUG

Copanlisib

Intravenous Infusion

DRUG

Acalabrutinib

Capsule, taken by mouth twice daily

Sponsors & Collaborators

  • Bayer

    collaborator INDUSTRY

  • Inhye Ahn

    lead OTHER

Principal Investigators

  • Inhye Ahn, MD · Dana-Farber Cancer Institute

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-02-18
Primary Completion
2023-03-01
Completion
2028-03-01
FDA Drug
Yes

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04685915 on ClinicalTrials.gov